Patents Assigned to Insulet Corporation
  • Patent number: 12128215
    Abstract: Embodiments of the present disclosure relate to approaches for more efficiently measuring glucose levels using a wearable drug delivery device. In some embodiments, the wearable drug delivery device may include a needle deployment component including a cannula and an optical conduit deployable into a user, the cannula operable to deliver a liquid drug to the user. The wearable drug delivery device may further include a glucose monitor including an optical sensor, the optical sensor operable to measure a light output received via the optical conduit.
    Type: Grant
    Filed: September 28, 2021
    Date of Patent: October 29, 2024
    Assignee: INSULET CORPORATION
    Inventors: Steven Cardinali, David Nazzaro, Ian McLaughlin
  • Patent number: 12121700
    Abstract: Disclosed are techniques and a device operable to determine a total amount of insulin delivered to the user over a predetermined time period. The total amount of insulin includes a total basal dosage delivered in basal dosages and a total bolus dosage delivered in bolus dosages over the predetermined time period. A proportion of the total amount of insulin delivered to the user provided via the total basal dosage amount over the predetermined time period is calculated. In response determining the proportion of the total amount of insulin attributed to the total basal dosage amount of insulin exceeds a threshold, an average basal dosage to be delivered within a subsequent time period that is approximately equal to the threshold may be determined. An instruction may be generated and output to deliver a modified basal dosage that substantially maintains the average basal dosage over the subsequent time period.
    Type: Grant
    Filed: July 16, 2021
    Date of Patent: October 22, 2024
    Assignee: INSULET CORPORATION
    Inventors: James Graham, Joon Bok Lee, Jason O'Connor
  • Patent number: 12121701
    Abstract: Disclosed herein are systems and methods for the delivery of a co-formulation of insulin and a second drug, such as GLP-1, using an automated insulin delivery system. In a first embodiment, a dose of insulin is calculated by a medication delivery algorithm and a reduction factor is applied to account for the effect of second drug on the user's daily insulin requirement. In a second embodiment of the invention, a total amount of the second drug administered to the user during the past 24 hours is used to modify the correction factor and the insulin-to-carbohydrate ratio used by the medication delivery algorithm to cause a reduction in the insulin delivered to the user to account for the effect of the administration of the second drug portion of the co-formulation.
    Type: Grant
    Filed: January 24, 2022
    Date of Patent: October 22, 2024
    Assignee: INSULET CORPORATION
    Inventors: Joon Bok Lee, Jason O'Connor, Yibin Zheng, Ashutosh Zade
  • Patent number: 12115351
    Abstract: The exemplary embodiments may provide a secure framework for devices in a drug delivery system to wirelessly communicate. The secure framework may use encrypted keys to carry credentials and to specify the rights of the devices presenting the credentials. The devices in the drug delivery system present the keys at the time that they wish to wirelessly communicate with other devices in the drug delivery system. The devices receiving such keys, decrypt the keys and verify if the credentials are valid. If the credentials are valid, a wireless communication session between devices may be established.
    Type: Grant
    Filed: September 30, 2021
    Date of Patent: October 15, 2024
    Assignee: INSULET CORPORATION
    Inventor: David Nazzaro
  • Patent number: 12106837
    Abstract: Methods, devices, and systems of delivering infusion fluid (e.g., medication such as insulin) can detect, at multiple times during a dispensation period of time, a pressure level of the infusion fluid in an infusion fluid pathway, either directly or indirectly. Based on the detected pressure levels, one or more actual dispensation times that are after an intended dispensation time can be determined. In some cases, methods, devices, and systems provided herein can use variable occlusion alarm thresholds, which can depend on variables such as an age of an infusion set and/or a current analyte level. In some cases, methods, devices, and systems provided herein can automate medication delivery and use the actual dispensation times in a control algorithm determining medication deliveries.
    Type: Grant
    Filed: February 27, 2020
    Date of Patent: October 1, 2024
    Assignee: Insulet Corporation
    Inventors: Bryan Mazlish, Lane Desborough, Ravi Shankar Rontala Raghunathan
  • Patent number: 12097355
    Abstract: The exemplary embodiments may provide a drug delivery device that receives glucose level values for a user (e.g., a diabetic patient) and based on the glucose level values, determines when the user has consumed a meal. In some embodiments, the drug delivery device may calculate an appropriate bolus dose and automatically deliver the drug bolus to the user. In some embodiments, instead of detecting the meal, the user may announce the meal, such as by activating an element on the drug delivery device or on a management device for the drug delivery device. Responsive to the meal announcement, the drug delivery device may calculate the drug bolus dose and deliver the drug bolus. In conjunction with the delivery of the drug bolus, the drug delivery device may relax one or more safety constraints for a relaxation period following the drug bolus delivery so that additional basal drug may be delivered, if needed, under relaxed constraints.
    Type: Grant
    Filed: December 20, 2023
    Date of Patent: September 24, 2024
    Assignee: INSULET CORPORATION
    Inventors: Rangarajan Narayanaswami, Yibin Zheng, Mert Sevil, William Whiteley, Saeed Salavati, Sam Carl
  • Patent number: 12097352
    Abstract: The disclosed embodiments are directed to a wearable automatic drug delivery device configured to provide basal-only dosing of insulin. In a primary embodiment, the wearable drug delivery device is configured to provide automatic operation and provides audible alerts and visual status indicators to the patient. In other embodiments, the patient may have some degree of control over the operation of the device by providing tapping gestures on housing of the device. In yet another embodiment, the patient may provide input and receive status from the device via an application executing on a portable computing device in wireless communication with the wearable drug delivery device.
    Type: Grant
    Filed: August 26, 2021
    Date of Patent: September 24, 2024
    Assignee: INSULET CORPORATION
    Inventors: Jason O'Connor, Matthew Alles, Robert Sanzone, Craig Brodeur, Joseph Melo, Christopher Williams, Noel Schaeffer
  • Patent number: 12090301
    Abstract: Disclosed are a system, methods and computer-readable medium products that provide safety constraints for an insulin-delivery management program. Various examples provide safety constraints for a control algorithm-based drug delivery system that provides automatic delivery of a drug based on sensor input. Glucose measurement values may be received at regular time intervals from a sensor. A processor may predict future glucose values based on prior glucose measurement values. The safety constraints assist in safe operation of the drug delivery system during various operational scenarios. In some examples, predicted future glucose values may be used to implement safety constraints that mitigate under-delivery or over-delivery of the drug while not overly burdening the user of the drug delivery system and without sacrificing performance of the drug delivery system. Other safety constraints are also disclosed.
    Type: Grant
    Filed: May 6, 2019
    Date of Patent: September 17, 2024
    Assignee: INSULET CORPORATION
    Inventors: Jason O'Connor, Joon Bok Lee, Trang Ly, Yibin Zheng, Thomas Arnold Peyser, Jennifer Lena Schneider
  • Patent number: 12090498
    Abstract: Disclosed herein are various embodiments of a pump mechanism comprising a rigid structure having an open end and a closed end, a plunger disposed in the open end of the rigid structure, and a flexible, fluid-proof sheet of material attached to an inner wall of the rigid structure and bonded to the head of the plunger such as to form a fluid barrier between the interior of the rigid structure and the plunger. Movement of the plunger toward the closed end of the rigid structure causes a rolling corner to be formed between the head of the plunger and the rigid structure and a fluid contained within the pump chamber to be forced out of the pump chamber via a fluid port defined in the closed end of the rigid structure.
    Type: Grant
    Filed: August 18, 2022
    Date of Patent: September 17, 2024
    Assignee: INSULET CORPORATION
    Inventors: Soroush Kamrava, Daniel Allis
  • Patent number: 12076160
    Abstract: Systems, methods, and devices provide alarms and alerts in an on-body networked diabetes management system. Methods may include receiving glucose sensor data from a continuous glucose monitor and determining a dosage of insulin delivery based at least in part on the glucose sensor data. The method may include detecting an alarm or alert condition, and sending a wireless communication regarding the alarm or alert condition to a remote user-interface device. The method may include triggering an audible, visual, or haptic alarm or alert on the insulin delivery device unless an acknowledgement of the alarm or alert condition is received within a predetermined period of time.
    Type: Grant
    Filed: July 29, 2021
    Date of Patent: September 3, 2024
    Assignee: Insulet Corporation
    Inventors: Bryan Mazlish, Sabine Kabel-Eckes, Shannon Sieber, Jeff Boissier, George Crothall, Yean Wah Chan
  • Patent number: 12064591
    Abstract: Some embodiments of an infusion pump system may be configured to wirelessly communicate with other devices using near field communication (NFC). In particular embodiments, by incorporating near field communication capabilities into the infusion pump system, user communications with the infusion pump system can be enhanced and simplified.
    Type: Grant
    Filed: August 24, 2021
    Date of Patent: August 20, 2024
    Assignee: Insulet Corporation
    Inventor: Mark C. Estes
  • Patent number: 12053615
    Abstract: Some embodiments of an infusion pump assembly may be equipped with one or more components to facilitate wireless operation of an infusion pump via a user-operated mobile device. In some embodiments, the mobile device and/or the infusion pump may prompt the user to confirm acceptance of a wirelessly communicated command to prevent an operation by the infusion pump (e.g., a dispensation of medicine) that is not desired by the user.
    Type: Grant
    Filed: April 28, 2021
    Date of Patent: August 6, 2024
    Assignee: INSULET CORPORATION
    Inventors: Mark C. Estes, Wenkang Qi, David Thrower
  • Patent number: 12042630
    Abstract: The embodiments described herein may relate to methods and systems for adjusting insulin delivery. Some methods and systems may be configured to adjust insulin delivery to personalize automated insulin delivery for a person with diabetes. Such personalization may include adjusting user specific dosage parameters in response to a user provided insulin delivery amount, including a user provided insulin delivery amount that varies from a recommended insulin delivery amount.
    Type: Grant
    Filed: January 4, 2021
    Date of Patent: July 23, 2024
    Assignee: Insulet Corporation
    Inventors: Bryan Mazlish, Lane Desborough, Ross Naylor
  • Patent number: 12036389
    Abstract: Exemplary embodiments provide an approach to predicting meal and/or exercise events for an insulin delivery system that otherwise does not otherwise identify such events. The insulin delivery system may use a model of glucose insulin interactions that projects estimated future glucose values based on a history of glucose values and insulin deliveries for a user. The predictions of meal events and/or exercise events may be based on residuals between actual glucose values and predicted glucose values. The exemplary embodiments may calculate a rate of change of the residuals over a period of time and compare the rate of change to thresholds to determine whether there likely has been a meal event or an exercise event. The insulin delivery system may then take measures to account for the meal event or the exercise event by the user.
    Type: Grant
    Filed: January 6, 2021
    Date of Patent: July 16, 2024
    Assignee: INSULET CORPORATION
    Inventors: Joon Bok Lee, Yibin Zheng, Jason O'Connor
  • Patent number: 11992653
    Abstract: Disclosed are examples for a system for drug delivery and components thereof. The system may include an on-body pump device and a secondary unit. The on-body pump device may include a reservoir and a fluid pathway. The reservoir may be configured to hold a liquid drug. The secondary unit may be removably coupled to the on-body pump device. The secondary unit may be configured to receive a prefilled cartridge containing a liquid drug, expel the liquid drug from the prefilled cartridge, and deliver the liquid drug to the reservoir of the on-body pump device via the fluid pathway. Examples of variations to the secondary unit are also disclosed.
    Type: Grant
    Filed: July 18, 2019
    Date of Patent: May 28, 2024
    Assignee: INSULET CORPORATION
    Inventors: Jason O'Connor, Ian McLaughlin, Daniel Allis, David Nazzaro
  • Patent number: 11986630
    Abstract: The exemplary embodiments attempt to identify impending hypoglycemia and/or hyperglycemia and take measures to prevent the hypoglycemia or hyperglycemia. Exemplary embodiments may provide a drug delivery system for delivering insulin and glucagon as needed by a user of the drug delivery system. The drug delivery system may deploy a control system that controls the automated delivery of insulin and glucagon to a patient by the drug delivery system. The control system seeks among other goals to avoid the user experiencing hypoglycemia or hyperglycemia. The control system may employ a clinical decision support algorithm as is described below to control delivery of insulin and glucagon to reduce the risk of hypoglycemia or hyperglycemia and to provide alerts to the user when needed. The control system assesses whether the drug delivery system can respond enough to avoid hypoglycemia or hyperglycemia and generates alerts when manual action is needed to avoid hypoglycemia or hyperglycemia.
    Type: Grant
    Filed: February 12, 2020
    Date of Patent: May 21, 2024
    Assignee: INSULET CORPORATION
    Inventors: Joon Bok Lee, Ashutosh Zade, Jason O'Connor, Trang Ly, Yibin Zheng, Connor Gullifer, Kyle Grover
  • Patent number: 11969579
    Abstract: A method of insulin delivery, the method may include obtaining one or more blood glucose readings of a user, and, based on the blood glucose readings, generating a set of insulin delivery actions that may include delivery of a baseline basal rate or predefined variations of the baseline basal rate. The method may also include monitoring previous insulin delivery actions to the user to determine whether the previous insulin delivery actions include insulin beyond a threshold amount, where the previous insulin delivery actions may include delivery of the baseline basal rate or predefined variations of the baseline basal rate, and, based on the previous insulin delivery actions including insulin beyond the threshold amount, adjusting the set of insulin delivery actions.
    Type: Grant
    Filed: June 11, 2021
    Date of Patent: April 30, 2024
    Assignee: Insulet Corporation
    Inventors: Bryan Mazlish, Lane Desborough
  • Patent number: 11957875
    Abstract: Disclosed are a device, system, methods and computer-readable medium products that provide an updated insulin-to-carbohydrate ratio and an updated total daily insulin. The described processes may be used for periodic updating of the insulin-to-carbohydrate ratio and the total daily insulin. The insulin-to-carbohydrate ratio and/or the total may be used in the calculation of new doses of insulin that a drug delivery device may be commanded to deliver to a user.
    Type: Grant
    Filed: December 4, 2020
    Date of Patent: April 16, 2024
    Assignee: INSULET CORPORATION
    Inventors: Yibin Zheng, Joon Bok Lee, Steven Cardinali, Jason O'Connor, Eric Benjamin, Ian McLaughlin, David Nazzaro, Ashutosh Zade
  • Patent number: 11957874
    Abstract: Some embodiments an infusion pump system can be configured to modify alarm limit parameters as the user's insulin load increases or decreases. Moreover, in particular embodiments, the infusion pump system can be configured to provide a “missed bolus” or “missed meal” alarm in response to the user's blood glucose characteristics, the user's insulin load information, or the like.
    Type: Grant
    Filed: July 14, 2020
    Date of Patent: April 16, 2024
    Assignee: INSULET CORPORATION
    Inventor: Mark C. Estes
  • Patent number: D1024314
    Type: Grant
    Filed: June 1, 2022
    Date of Patent: April 23, 2024
    Assignee: INSULET CORPORATION
    Inventors: Derek Rund, Josh Haldeman, Mary Friedl, Michael Palmisano, Tony Guard, Jeffrey Barnes, Ayden Henson, David Seward, Steven Cardinali, Matthew Alles, Robert Sanzone